Table 1. Prospective adjuvant trials that compare directly an EGFR-TKI with platinum-based chemotherapy (no adjuvant chemotherapy allowed in the EGFR-TKI arm).
| Author, phase (ref.) | Population | Stage, biomarker selection | No. of pts, design | Length of exposure to EGFR-TKI (years) | Primary end-point | Results for primary end-point |
|---|---|---|---|---|---|---|
| Zhong et al., 3 (6) | Asiatic | II–IIIA(N1,N2)*, EGFR mutation≠ | 222, gefitinib vs. cisplatin/vinorelbine | 2 | DFS | 28.7 vs. 18.0 months, HR =0.60; P=0.0054 |
| Yue et al., 2 (7) | Asiatic | IIIA*, EGFR mutation≠ | 102, erlotinib vs. cisplatin/vinorelbine | 2 | 2-year DFS rate | 81.35% vs. 44.62%, P<0.001 |
*, 7th TNM staging; ≠, exon 19 deletion or exon 21 L858R. DFS, disease-free survival; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; HR, hazard ratio; No., number; OS, overall survival; pts, patients; vs., versus; ref., reference.